Background Mpox emerged as a significant global public health concern during the 2022–2023 outbreak, impacting populations in ...

With seven agents approved for renal cell carcinoma within the past few years, there has undoubtedly been progress in treating this disease. However, patients with poor-risk features remain a ...

Independent review committee（IRC） assessment showed an overall response rate (ORR) of 68.8% and a disease control ... advanced or metastatic NSCLC harboring EGFR mutations.

Around 70% of NSCLC patients are diagnosed at locally advanced or metastatic disease stages that cannot be surgically resected. EGFR mutations are particularly prevalent in Asian NSCLC patients, ...

genetics, and viral susceptibility.” Reference: Spalinger MR, Sanati G, Chatterjee P, et al. Tofacitinib mitigates the increased SARS-CoV-2 infection susceptibility caused by an IBD risk variant in ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection ... commonly associated with autoimmune diseases, can increase expression of the SARS-CoV-2 receptor ACE2, making cells ...

Arexvy has been approved for the prevention of lower respiratory tract disease caused by RSV in all individuals 60 years of age and older and for those aged 50 to 59 years at increased risk.

A team of researchers led by Mayo Clinic has found that only 250 of 3,500 less-common mutations in the BRCA2 gene increase the risk of breast cancer. (Eli Hartman/Odessa American via AP) ...

TLC Baylen Dupree was officially diagnosed with Tourette Syndrome just ahead of her 18th ... "That is so important to me, and [it] can be a really big risk when you are doing a TV show — how ...

Germline mutations are hereditary and affect every cell in the body. Because primary and metastatic tumours from ... common missense variants with known disease associations, and found eight ...

C Klein is a Lichtenberg Professor of Clinical and Molecular Neurogenetics at the Department of Neurology at Lübeck University, Lübeck, Germany; MG Schlossmacher is an assistant professor of ...

Sunvozertinib received FDA priority review for advanced EGFR exon 20 insertion-positive non-small cell lung cancer progressing after chemotherapy. Priority review was granted by the FDA for ...